
Omlyclo set to become commercially available in Europe
The drug Omlyclo, the first and only omalizumab biosimilar in Europe, will be commercially available in the European market, biopharmaceutical company Celltrion has announced. Omlyclo, a drug used to treat chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps, will be available in Norway… Read More

